Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis

New England Journal of Medicine

Volumn 368, Issue 4, 2013, Pages 320-332

  Macdougall, Iain C ^a   Provenzano, Robert ^b   Sharma, Amit ^c   Spinowitz, Bruce S ^d   Schmidt, Rebecca J ^f   Pergola, Pablo E ^g   Zabaneh, Raja I ^h   Tong Starksen, Sandra ⁱ   Mayo, Martha R ⁱ   Tang, Hong ⁱ   Polu, Krishna R ⁱ   Duliege, Anne Marie ⁱ   Fishbane, Steven ^e  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b St Clair Specialty Physicians   (United States)

^c Boise Kidney and Hypertension Institute   (United States)

^d Nephrology Associates   (United States)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^f WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Renal Associates   (United States)

^h Northwest Louisiana Nephrology   (United States)

ⁱ AFFYMAX RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINESATIDE;

ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL EVALUATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART DEATH; HEART MUSCLE ISCHEMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFUSION RELATED REACTION; INJECTION SITE REACTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SUDDEN DEATH; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; URINARY TRACT INFECTION; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM;

EID: 84872808811     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1203166     Document Type: Article

References (29)

1. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2:1175-8.
2. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-8.
3. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992-1000.
4. Macdougall IC, Lewis NP, Saunders MJ, et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990;335:489-93. [Erratum, Lancet 1990;335:614.]
5. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16:Suppl 3:3-13.
6. Kiss Z, Elliott S, Jedynasty K, Tesar V, Szegedi J. Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact. Eur J Clin Pharmacol 2010;66:331-40.
7. Macdougall IC. CERA (continuous erythropoietin-receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005;4:436-40.
8. Idem. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 2008;3:200-7.
9. Woodburn KW, Holmes CP, Wilson SD, et al. Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats. Xenobiotica 2012;42:660-70.
10. Livnah O, Stura EA, Johnson DL, et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 Å. Science 1996;273:464-71.
11. Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006;34:1303-11.
12. Macdougall IC, Wiecek A, Tucker B, et al. Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol 2011;6:2579-86.
13. Eckardt K-U, Berns JS, Rocco MV, Kasiske BL. Definition and classification of CKD: the debate should be about patient prognosis - a position statement from KDOQI and KDIGO. Am J Kidney Dis 2009;53:915-20.
14. Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009;4:33-8.
15. Chang A, Kramer H. Should eGFR and albuminuria be added to the Framingham Risk Score? Chronic kidney disease and cardiovascular disease risk prediction. Nephron Clin Pract 2011;119(2):c171-c178.
16. Go AS, Chertow GM, Fan D, Mc-Culloch CE, Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
17. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
18. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84.
19. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32.
20. Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013;368:307-19.
21. Postorino M, Marino C, Tripepi G, et al. Prognostic value of the New York Heart Association classification in end-stage renal disease. Nephrol Dial Transplant 2007;22:1377-82.
22. Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363:1146-55.
23. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791-8.
24. U.S. Renal Data System. 2011 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010.
25. Shamseddin MK, Parfrey PS. Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol 2011;7:145-54.
26. Woodburn KW, Wilson SD, Fong K-L, et al. Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis stimulating agent, in monkeys. Haematologica 2008;93:1376-9.
27. Herzog CA, Stief JW, Collins AJ, Gilbertson DT. Cause-specific mortality of dialysis patients after coronary revascularization: why don't dialysis patients have better survival after coronary intervention? Nephrol Dial Transplant 2008;23:2629-33.
28. Clarkson MR, Friedewald JJ, Eustace JA, Rabb H. Acute kidney injury. In: Brenner BM, ed. Brenner & Rector's The kidney. 8th ed. Philadelphia: Saunders Elsevier, 2007:943-86.
29. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69.